Valion Bio board chair Jensen lays out case for Entolimod amid company turnaround
In an October 5, 2026 release, new board chair Thomas Jensen cited government funding, FDA designations and in-house manufacturing as reasons to advance the radiation drug candidate.
Valion Bio, Inc. filed an 8-K on October 6, 2026 disclosing a press release issued October 5, 2026 in which new Board Chair Thomas Jensen outlined his perspectives on advancing Entolimod, citing the company's biotech turnaround experience at Allarity Therapeutics.1 Entolimod is an investigational Toll-like receptor 5 agonist being developed as a potential medical countermeasure for acute radiation syndrome.1
Jensen, who has more than 20 years of biotechnology and oncology experience and serves as CEO and a Director of Nasdaq-listed Allarity Therapeutics, Inc.1, pointed to several factors supporting the program. Entolimod's development has been supported by approximately $35.6 million in non-dilutive funding from several U.S. government agencies, and the program holds FDA Fast Track and Orphan Drug designations for ARS.1 It is also backed by a substantial body of human safety data and by supply chain control through Valion's wholly owned U.S.-based CDMO, Velocity Bioworks.1 The company noted that, to its knowledge, there is no FDA-approved treatment for gastrointestinal ARS.1
At Allarity, since becoming CEO in December 2023, Jensen has simplified its capital structure, streamlined the organization and reduced costs while concentrating resources on its lead candidate stenoparib, during which time Allarity advanced its Phase 2 ovarian cancer program, received FDA Fast Track designation for stenoparib, strengthened its intellectual property position and secured drug supply for later-stage development.1
The release states Jensen is working as Chair with Interim CEO Dean Zikria, President, COO and CFO Lisa Wolf, and the Board to align Valion's strategic priorities with execution.1 Separately, the filing describes Valion's pipeline as also including Entolasta, a next-generation TLR5 agonist for broader therapeutic applications including oncology supportive care, along with potential programs in neutropenia and immune dysfunction.1 Velocity Bioworks is described as Valion's wholly owned subsidiary, a biologics contract development and manufacturing organization supporting Valion's internal pipeline.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.